ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
210 |
113K |
15 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
210
|
113K
|
15
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
12 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
12
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
2 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
2
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
210 |
113K |
22 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
210
|
113K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.1K |
723K |
8 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.1K
|
723K
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
25 |
14/06/24 |
14/06/24 |
General
|
11K
|
4.0M
|
25
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
6 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
537
|
206K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Confirms No Supply Disruptions for Clinical Trials
|
|
ma420
|
11 |
4.7K |
1 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
11
|
4.7K
|
1
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
210 |
113K |
18 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
210
|
113K
|
18
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
19 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
537
|
206K
|
19
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.1K |
723K |
2 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.1K
|
723K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.1K |
723K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
2.1K
|
723K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
0 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
110
|
37K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
37K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
0 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
110
|
37K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
26K |
1 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
26K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
ma420
|
2.1K |
723K |
2 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
2.1K
|
723K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Application for quotation of securities - RAC
|
|
ma420
|
1 |
948 |
9 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
1
|
948
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model
|
|
ma420
|
82 |
26K |
14 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
82
|
26K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
888 |
304K |
11 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
888
|
304K
|
11
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.6M |
3 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
22K
|
7.6M
|
3
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
26K |
1 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
62
|
26K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
2 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
537
|
206K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
|
|
ma420
|
110 |
37K |
27 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
110
|
37K
|
27
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
768K |
41 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
2.2K
|
768K
|
41
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
ma420
|
10 |
4.7K |
3 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
10
|
4.7K
|
3
|
|
ASX - By Stock
|
COV |
Re:
Cleo - General discussion
|
|
ma420
|
2 |
1.1K |
1 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
2
|
1.1K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
ma420
|
10 |
4.7K |
2 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
10
|
4.7K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
26 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
537
|
206K
|
26
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
210 |
113K |
16 |
09/06/24 |
09/06/24 |
ASX - By Stock
|
210
|
113K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
248 |
68K |
3 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
248
|
68K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
248 |
68K |
8 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
248
|
68K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
DXB options
|
|
ma420
|
46 |
24K |
0 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
46
|
24K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
DXB options
|
|
ma420
|
46 |
24K |
1 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
46
|
24K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
ma420
|
636 |
227K |
10 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
636
|
227K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
17 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
537
|
206K
|
17
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Confirms No Supply Disruptions for Clinical Trials
|
|
ma420
|
11 |
4.7K |
16 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
11
|
4.7K
|
16
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
ma420
|
210 |
113K |
28 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
210
|
113K
|
28
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
21 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
537
|
206K
|
21
|
|
ASX - By Stock
|
NTI |
NTI - Media & News
|
|
ma420
|
0 |
308 |
1 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
0
|
308
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
ma420
|
120 |
42K |
26 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
120
|
42K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
ma420
|
35 |
12K |
5 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
12K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
768K |
1 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
768K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
768K |
0 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
768K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bonus Options Offer Results
|
|
ma420
|
35 |
12K |
66 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
35
|
12K
|
66
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
20 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
537
|
206K
|
20
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
537 |
206K |
12 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
537
|
206K
|
12
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.6M |
4 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
22K
|
7.6M
|
4
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
ma420
|
2.2K |
768K |
14 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
2.2K
|
768K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
ma420
|
248 |
68K |
3 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
248
|
68K
|
3
|
|